B+
Bull case
25%
Probability
Target price
$73.00
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
TECH
Bio-TechneCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
60%
Probability
Target price
$72.50
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
B-
Bear case
15%
Probability
Target price
$55.00
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-14
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+58.6
Score
AI commentary
Post-earnings evidence remains mixed: the official release showed 3% organic Q4 growth and better margins, but adjusted EPS declined slightly and full-year revenue was flat. The August 13 anchor of $72.17 was only about 1.15% below the $73 cash consideration, but the packet does not provide the prior-session close, so the immediate earnings reaction cannot be quantified. The latest surfaced analyst action predates the print and was tied to the acquisition, not new operating estimates. This remains a cautious event-driven monitoring view.
RankAlpha Sentiment Codex - 2026-08-14
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-12eventQ4 FY2026 results showed modest organic growth and margin improvementMedium impact
Bio-Techne reported Q4 revenue of $321.2 million, up 1% reported and 3% organically, with adjusted operating margin rising to 32.2%. Adjusted EPS declined slightly to $0.52, while full-year revenue remained flat and full-year adjusted EPS was $1.93. [#SEC-8K-2026-08-12]
2026-11-01catalystPotential improvement in biotech and academic customer demandHigh impact
Management previously cited early signs that funding activity and customer purchasing could realign, while large pharma, spatial biology, and GMP proteins remained stronger growth areas. This remains a monitoring thesis rather than a confirmed reacceleration. [#SEC-8K-2026-05-06]
2026-11-12eventMerck acquisition completion at $73 per shareMedium impact
The announced cash acquisition by Merck KGaA remains the dominant valuation anchor, with closing expected in late 2026 or early 2027 subject to customary conditions. [#SEC-8K-2026-08-12]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-14 • Updated nightlySource: Internal modelMethodology